|
176 Companies |
|
232 Products |
|
232 Products |
|
108 Mechanisms of Action |
|
9 Trials |
|
1978 News |
|
| 12345678910111213...4142» |
- Aphexda (motixafortide) / BioLineRx, Gloria Pharma
Phase classification: Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients (clinicaltrials.gov) - Sep 19, 2024
P2, N=42, Completed, Sponsor: BioLineRx, Ltd.
Phase classification: P2a --> P2
- ||| crenolanib (ARO-002) / AROG
Enrollment change: Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations (clinicaltrials.gov) - Feb 15, 2024
P2, N=14, Completed, Sponsor: Arog Pharmaceuticals, Inc.
Phase classification: P2a --> P2 N=20 --> 14
- || clofarabine / Generic mfg.
Enrollment change: Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. (clinicaltrials.gov) - Feb 15, 2024
P1, N=18, Completed, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
N=20 --> 14 N=36 --> 18
- ||| Pixuvri (pixantrone) / Servier
Enrollment change: Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Sep 18, 2023
P1/2, N=12, Completed, Sponsor: CTI BioPharma
N=36 --> 18 N=119 --> 12
- ||| uproleselan sodium (APL-106) / GlycoMimetics
Trial completion, Combination therapy: Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML (clinicaltrials.gov) - May 17, 2019
P1/2, N=91, Completed, Sponsor: GlycoMimetics Incorporated
N=119 --> 12 Active, not recruiting --> Completed
- || Farydak (panobinostat) / Secura Bio
Trial completion, Combination therapy, Epigenetic controller, Metastases: Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 22, 2019
P1, N=29, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
Trial completion: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) - Apr 20, 2019
P3, N=260, Completed, Sponsor: Neovii Biotech
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Enrollment change, Trial termination: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Feb 26, 2019
P2, N=20, Terminated, Sponsor: University of Nebraska
Active, not recruiting --> Completed N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
- || Xospata (gilteritinib) / Astellas
Trial primary completion date: Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 20, 2019
P1/2, N=265, Completed, Sponsor: Astellas Pharma Global Development, Inc.
N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections. Trial primary completion date: Nov 2015 --> Aug 2017
- | decitabine / Generic mfg.
Trial completion: Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 19, 2019
P2, N=546, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2015 --> Aug 2017 Active, not recruiting --> Completed
- || Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Feb 18, 2019
P1/2, N=50, Completed, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Vonjo (pacritinib) / SOBI
Trial completion, Enrollment change: Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (clinicaltrials.gov) - Jan 25, 2019
P1, N=13, Completed, Sponsor: Bhavana Bhatnagar
Active, not recruiting --> Completed Suspended --> Completed | N=60 --> 13
- | NN1213 / Novo Nordisk
Trial completion, Phase classification: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Jan 24, 2019
P1, N=90, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Suspended --> Completed | N=60 --> 13 Active, not recruiting --> Completed | Phase classification: PN/A --> P1
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial completion: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Jan 18, 2019
P1, N=16, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed | Phase classification: PN/A --> P1 Active, not recruiting --> Completed
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 15, 2019
P2, N=11, Completed, Sponsor: Rondeep Brar
Active, not recruiting --> Completed Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017
- | Ninlaro (ixazomib) / Takeda
Trial completion, Trial completion date, Combination therapy: Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 13, 2018
P1, N=30, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017 Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Aug 2017
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion, Trial completion date, Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Nov 30, 2018
P2, N=22, Completed, Sponsor: Sellas Life Sciences Group
Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Aug 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2018
- | dilanubicel (DVX101) / Deverra Therapeutics
Phase classification, Enrollment change, Trial termination: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 26, 2018
P1, N=7, Terminated, Sponsor: Nohla Therapeutics, Inc.
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2018 Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated
- | lenalidomide / Generic mfg.
Enrollment change, Trial termination: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) - Oct 17, 2018
P2, N=32, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: DC Vaccination for Postremission Therapy in AML (clinicaltrials.gov) - Oct 12, 2018
P1/2, N=13, Completed, Sponsor: Ludwig-Maximilians - University of Munich
N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy Recruiting --> Completed | N=20 --> 13 | Trial completion date: Apr 2019 --> Sep 2018 | Trial primary completion date: May 2017 --> Mar 2018
- | cyclophosphamide / Generic mfg.
Trial completion date, Trial termination: Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 12, 2018
P1, N=25, Terminated, Sponsor: Washington University School of Medicine
Recruiting --> Completed | N=20 --> 13 | Trial completion date: Apr 2019 --> Sep 2018 | Trial primary completion date: May 2017 --> Mar 2018 Trial completion date: Oct 2018 --> Mar 2018 | Active, not recruiting --> Terminated; Low accrual rate
- | Trial termination: Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=241, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Trial completion date: Oct 2018 --> Mar 2018 | Active, not recruiting --> Terminated; Low accrual rate Completed --> Terminated
- | decitabine / Generic mfg.
Trial completion, Trial completion date: Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 2, 2018
P2, N=114, Completed, Sponsor: Washington University School of Medicine
Completed --> Terminated Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017
- | CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Gene therapy: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) - Oct 2, 2018
P1/2, N=7, Completed, Sponsor: Cell Medica Ltd
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017 Recruiting --> Completed | N=18 --> 7 | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: May 2019 --> May 2018
- | clofarabine / Generic mfg.
Trial completion, Enrollment change: Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) (clinicaltrials.gov) - Sep 7, 2018
P1/2, N=9, Completed, Sponsor: University Hospital Southampton NHS Foundation Trust
Recruiting --> Completed | N=18 --> 7 | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: May 2019 --> May 2018 Active, not recruiting --> Completed | N=20 --> 9
- | Yervoy (ipilimumab) / BMS
Enrollment change: Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 5, 2018
P1, N=26, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=20 --> 9 N=48 --> 26
- | cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Aug 31, 2018
P2, N=142, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
N=48 --> 26 Active, not recruiting --> Completed | N=92 --> 142
- | Onrigin (laromustine) / Vion
Enrollment change, Trial termination: Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine (clinicaltrials.gov) - Aug 29, 2018
P2, N=25, Terminated, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | N=92 --> 142 N=52 --> 25 | Active, not recruiting --> Terminated
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Phase classification, Enrollment change, Trial termination: Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) - Aug 23, 2018
P1, N=7, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
N=52 --> 25 | Active, not recruiting --> Terminated Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply
- | Qinprezo (vosaroxin) / Denovo
Trial completion, Combination therapy: VALOR: Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML (clinicaltrials.gov) - Aug 22, 2018
P3, N=711, Completed, Sponsor: Sunesis Pharmaceuticals
Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Phase classification, Trial termination: Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - Aug 20, 2018
P1, N=14, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Phase classification: P=N/A --> P1 | Active, not recruiting --> Terminated; Poor accrual
- | Trial completion date, Trial termination: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=1000, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Phase classification: P=N/A --> P1 | Active, not recruiting --> Terminated; Poor accrual Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual
- | Trial completion: GIMEMAAML1310: Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 6, 2018
P2, N=515, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Active, not recruiting --> Completed
- | etoposide IV / Generic mfg., cytarabine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation (clinicaltrials.gov) - Aug 1, 2018
P3, N=144, Completed, Sponsor: University of Ulm
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
- |||| Vonjo (pacritinib) / SOBI
Trial completion date, Trial suspension, Trial primary completion date: Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (clinicaltrials.gov) - Jul 26, 2018
P1, N=60, Suspended, Sponsor: Bhavana Bhatnagar
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018 Trial completion date: May 2018 --> Sep 2018 | Recruiting --> Suspended | Trial primary completion date: May 2018 --> Sep 2018
- | tetradecanoylphorbol acetate (PD-616) / Biosuccess Biotech, Rich Pharma
Enrollment change: Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 24, 2018
P1/2, N=13, Terminated, Sponsor: Biosuccess Biotech Co., Ltd.
Trial completion date: May 2018 --> Sep 2018 | Recruiting --> Suspended | Trial primary completion date: May 2018 --> Sep 2018 N=33 --> 13
- | Trial completion, Trial completion date, Trial primary completion date: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=2545, Completed, Sponsor: Children's Oncology Group
N=33 --> 13 Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018
- | cytarabine / Generic mfg.
Enrollment change, Trial termination: Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior (clinicaltrials.gov) - Jul 17, 2018
P2/3, N=10, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018 N=40 --> 10 | Recruiting --> Terminated; Low accrual
- | NN1213 / Novo Nordisk
Trial completion: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Jul 11, 2018
P=N/A, N=16, Completed, Sponsor: University of Washington
N=40 --> 10 | Recruiting --> Terminated; Low accrual Active, not recruiting --> Completed
- ||| plerixafor / Generic mfg., decitabine / Generic mfg.
Trial completion: Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jul 2, 2018
P1, N=71, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Biopsy: Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=83, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Recruiting --> Completed
- | cytarabine / Generic mfg.
Trial completion date: Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=11, Completed, Sponsor: University of Rochester
Recruiting --> Completed Trial completion date: Dec 2014 --> Aug 2017
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Jun 12, 2018
P2, N=121, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Dec 2014 --> Aug 2017 Active, not recruiting --> Completed | N=61 --> 121
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial completion, Enrollment change: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 3, 2018
P=N/A, N=48, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=61 --> 121 Active, not recruiting --> Completed | N=90 --> 48
- || CYAD-01 / Celdara Medical, Celyad Oncology
Trial completion, Trial primary completion date, Metastases: Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) - Jun 3, 2018
P1, N=12, Completed, Sponsor: Celyad (formerly named Cardio3 BioSciences)
Active, not recruiting --> Completed | N=90 --> 48 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2018
- | Trial completion, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=80, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2018 Active, not recruiting --> Completed
- || BI 836858 / Boehringer Ingelheim
Trial completion: BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse (clinicaltrials.gov) - Jun 1, 2018
P1, N=30, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rydapt (midostaurin) / Novartis
Enrollment change, Trial termination, Combination therapy: Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2018
P2, N=13, Terminated, Sponsor: David Iberri
Active, not recruiting --> Completed N=36 --> 13 | Recruiting --> Terminated; Accrual factor
- | Enrollment change, Trial termination: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2018
P1, N=17, Terminated, Sponsor: Stanford University
N=36 --> 13 | Recruiting --> Terminated; Accrual factor N=30 --> 17 | Recruiting --> Terminated; Accrual factor
- | Trial completion, Trial completion date: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jun 1, 2018
P1, N=24, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=30 --> 17 | Recruiting --> Terminated; Accrual factor Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> May 2018